ClinicalTrials.gg
CompletedNCT04304534PACIFIC-AMIUpdated Apr 5, 2023Results posted

Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack

A Phase 2 interventional study of BAY2433334 and BAY2433334 matching placebo in Acute Myocardial Infarction, sponsored by Bayer. Completed at 160 sites in 14 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,601
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 440 studies in Myocardial Infarction with a site in United States — 41 open to participants now, 65 under way, 9 of them phase 3. Myocardial Infarction · United States.

Enrollment
60th of 301
1,601 · median 160
Started
2020
with 16 others
Phase 2
38 of 440
5 open now
Registered
348th of 440
by date

Among the 440 studies in Myocardial Infarction with a site in United States, this one is the 60th largest by enrollment of the 301 interventional ones that give a count, is one of 17 that started in 2020, is one of 38 in phase 2, and was the 348th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

41 of the 440 studies in Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Myocardial Infarction with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsalicylic acid +/- clopidogrel) in patients following a recent heart attack (myocardial infarction) that happens when a blood vessel in the heart suddenly becomes blocked. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.

03

Conditions studied

  • Acute Myocardial Infarction
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 45 years of age or older, at the time of signing the
  • Acute myocardial infarction (excluding MI associated with PCI or CABG revascularization procedures) with:

    • clinical symptoms of acute myocardial infarction AND
    • elevated biomarkers of myocardial necrosis (creatine kinase-muscle and brain isoenzyme [CK-MB] or cardiac troponins) AND
    • at least one of the following risk factors need to be fulfilled:

      • Age ≥ 65 years
      • Prior MI (before the index AMI event)
      • Prior peripheral arterial disease
      • Diabetes Mellitus
      • Prior coronary artery bypass grafting (CABG) AND
    • initial angiography and revascularization procedures, either PCI or CABG, as treatment for the index event performed before randomization. (Note: a planned, staged PCI procedure can be performed after randomization)
  • Plan for dual antiplatelet therapy (ASA + P2Y12 inhibitor) after hospital discharge for the index AMI
  • Randomization during hospitalization for the index AMI event and latest within 5 days of hospital admission
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent has to be signed before any study-specific procedure.

Exclusion criteria

Exclusion Criteria:

  • Hemodynamically significant ventricular arrhythmias or cardiogenic shock at time of randomization
  • Active bleeding; known bleeding disorder, history of major bleeding (intracranial, retroperitoneal, intraocular) or gastrointestinal bleeding within last 6 months of randomization
  • Planned use or requirement of full dose and long term anticoagulation therapy during study conduct.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,601 participants (actual)

Study arms

  • Experimental
    BAY 2433334 high dose

    Drug: BAY2433334

  • Experimental
    BAY 2433334 medium dose

    Drug: BAY2433334

  • Experimental
    BAY 2433334 low dose

    Drug: BAY2433334

  • Placebo comparator
    BAY2433334 matching placebo

    Other: BAY2433334 matching placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy - Number of Participants With Composite of CV Death, MI, Stroke and Stent Thrombosis (ST)

    CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included. Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. ST was defined incorporating diagnostic certainty as well as timing: "Definite" ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. "Probable" ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause

    Time frame: From baseline up to 52 weeks

  2. Safety - Number of Participants With BARC Bleeding Definition Type 2, 3 and 5

    Type 2: any overt, actionable sign of hemorrhage that doesn't fit the criteria for type 3 or 5 but meets at least one of the following criteria: 1) requires nonsurgical, med intervention by a HCP, 2) leads to hospital or rise in level of care, or 3) prompt eval. Type 3a: 1) overt bleed + Hg drop of 3 to \<5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation.

    Time frame: From baseline up to 52 weeks

Secondary outcomes

  1. Efficacy - Number of Participants With CV Death

    CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included.

    Time frame: From baseline up to 52 weeks

  2. Efficacy - Number of Participants With MI

    Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. According to MI Universal Definition from 2018 the diagnosis of MI requires combination of: 1. Presence of acute myocardial injury. 2. Evidence of acute myocardial ischemia derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging, or in case of post-mortem pathological findings irrespective of biomarker values.

    Time frame: From baseline up to 52 weeks

  3. Efficacy - Number of Participants With Stroke

    Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction.

    Time frame: From baseline up to 52 weeks

  4. Efficacy - Number of Participants With Stent Thrombosis

    ST was defined incorporating diagnostic certainty as well as timing: "Definite" ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. "Probable" ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause

    Time frame: From baseline up to 52 weeks

  5. Efficacy - Number of Participants With All Cause Mortality

    Time frame: From baseline up to 52 weeks

  6. Safety - Number of Participants With All Bleeding

    All bleeding events occurred from first intake of study intervention until 2 days after the last intake of study intervention

    Time frame: From baseline up to 52 weeks

  7. Safety - Number of Participants With BARC Bleeding Definition Type 3, 5

    Type 3a: 1) overt bleed + Hg drop of 3 to \<5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation.

    Time frame: From baseline up to 52 weeks

  8. Safety - Number of Participants With BARC Bleeding Definition Type 1,2,3,5

    Type 1: bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional. For BARC bleeding definition 2,3 and 5, please refer to second primary endpoint.

    Time frame: From baseline up to 52 weeks

07

Results

Posted Apr 5, 2023

Participant flow

Study was conducted at 157 centers in 14 countries or regions, between 17-Jun-2020 (first participant first visit) and 21-Feb-2022 (last participant last visit)

Participant flow — Overall Study
MilestoneAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
Started397401402401
Treated395397402399
Completed303317309309
Not completed94849392
Withdrew: Subject decision covid-19 pandemic related1010
Withdrew: Non-compliance with study drug0111
Withdrew: Lost to follow-up0123
Withdrew: Unspecific4222
Withdrew: Technical problems2234
Withdrew: Death7243
Withdrew: Withdrawal by subject7274
Withdrew: Physician decision4995
Withdrew: Subject decision34252526
Withdrew: Adverse event35403944

Outcome measures

PrimaryEfficacy - Number of Participants With Composite of CV Death, MI, Stroke and Stent Thrombosis (ST)

CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included. Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. ST was defined incorporating diagnostic certainty as well as timing: "Definite" ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. "Probable" ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause

Time frame:
From baseline up to 52 weeks
Reported as:
Count of participants · Participants
Efficacy - Number of Participants With Composite of CV Death, MI, Stroke and Stent Thrombosis (ST)
ParticipantsAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
Efficacy - Number of Participants With Composite of CV Death, MI, Stroke and Stent Thrombosis (ST)27242222
Statistical analysis
  • Asundexian 20 mg vs Asundexian 50 mg vs Placebo · Log Rank · p = = 0.8439 · Cox proportional hazard: 1.052 · 90% CI 0.687 to 1.612
  • Asundexian 20 mg vs Placebo · Log Rank · p = = 0.7562 · Cox proportional hazard: 1.096 · 90% CI 0.674 to 1.781
  • Asundexian 50 mg vs Placebo · Log Rank · p = = 0.978 · Cox proportional hazard: 1.008 · 90% CI 0.614 to 1.656
PrimarySafety - Number of Participants With BARC Bleeding Definition Type 2, 3 and 5

Type 2: any overt, actionable sign of hemorrhage that doesn't fit the criteria for type 3 or 5 but meets at least one of the following criteria: 1) requires nonsurgical, med intervention by a HCP, 2) leads to hospital or rise in level of care, or 3) prompt eval. Type 3a: 1) overt bleed + Hg drop of 3 to \<5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation.

Time frame:
From baseline up to 52 weeks
Reported as:
Count of participants · Participants
Safety - Number of Participants With BARC Bleeding Definition Type 2, 3 and 5
ParticipantsAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlaceboPooled Asundexian
Safety - Number of Participants With BARC Bleeding Definition Type 2, 3 and 530324236104
Statistical analysis
  • Placebo vs Pooled Asundexian · Log Rank · p = = 0.9158 · Hazard ratio (hr): 0.98 · 90% CI 0.713 to 1.347
  • Asundexian 10 mg vs Placebo · Log Rank · p = = 0.5633 · Hazard ratio (hr): 0.867 · 90% CI 0.577 to 1.302
  • Asundexian 20 mg vs Placebo · Log Rank · p = = 0.584 · Hazard ratio (hr): 0.875 · 90% CI 0.587 to 1.306
  • Asundexian 50 mg vs Placebo · Log Rank · p = = 0.417 · Hazard ratio (hr): 1.202 · 90% CI 0.828 to 1.747
SecondaryEfficacy - Number of Participants With CV Death

CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included.

Time frame:
From baseline up to 52 weeks
Reported as:
Count of participants · Participants
Efficacy - Number of Participants With CV Death
ParticipantsAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
Efficacy - Number of Participants With CV Death7452
Statistical analysis
  • Asundexian 20 mg vs Asundexian 50 mg vs Placebo · Cox proportional hazard: 1.275 · 90% CI 0.322 to 5.050
  • Asundexian 50 mg vs Placebo · Cox proportional hazard: 1.991 · 90% CI 0.479 to 8.273
SecondaryEfficacy - Number of Participants With MI

Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. According to MI Universal Definition from 2018 the diagnosis of MI requires combination of: 1. Presence of acute myocardial injury. 2. Evidence of acute myocardial ischemia derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging, or in case of post-mortem pathological findings irrespective of biomarker values.

Time frame:
From baseline up to 52 weeks
Reported as:
Count of participants · Participants
Efficacy - Number of Participants With MI
ParticipantsAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
Efficacy - Number of Participants With MI18201817
Statistical analysis
  • Asundexian 20 mg vs Asundexian 50 mg vs Placebo · Cox proportional hazard: 1.125 · 90% CI 0.696 to 1.819
  • Asundexian 20 mg vs Placebo · Cox proportional hazard: 1.181 · 90% CI 0.686 to 2.031
  • Asundexian 50 mg vs Placebo · Cox proportional hazard: 1.070 · 90% CI 0.613 to 1.866
SecondaryEfficacy - Number of Participants With Stroke

Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction.

Time frame:
From baseline up to 52 weeks
Reported as:
Count of participants · Participants
Efficacy - Number of Participants With Stroke
ParticipantsAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
Efficacy - Number of Participants With Stroke4302
SecondaryEfficacy - Number of Participants With Stent Thrombosis

ST was defined incorporating diagnostic certainty as well as timing: "Definite" ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. "Probable" ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause

Time frame:
From baseline up to 52 weeks
Reported as:
Count of participants · Participants
Efficacy - Number of Participants With Stent Thrombosis
ParticipantsAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
Efficacy - Number of Participants With Stent Thrombosis4544
SecondaryEfficacy - Number of Participants With All Cause Mortality
Time frame:
From baseline up to 52 weeks
Reported as:
Count of participants · Participants
Efficacy - Number of Participants With All Cause Mortality
ParticipantsAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
Efficacy - Number of Participants With All Cause Mortality107107
Statistical analysis
  • Asundexian 20 mg vs Asundexian 50 mg vs Placebo · Log Rank · p = = 0.6016 · Cox proportional hazard: 1.266 · 90% CI 0.603 to 2.658
  • Asundexian 20 mg vs Placebo · Log Rank · p = = 0.9945 · Cox proportional hazard: 0.996 · 90% CI 0.414 to 2.401
  • Asundexian 50 mg vs Placebo · Log Rank · p = = 0.4085 · Cox proportional hazard: 1.506 · 90% CI 0.667 to 3.405
SecondarySafety - Number of Participants With All Bleeding

All bleeding events occurred from first intake of study intervention until 2 days after the last intake of study intervention

Time frame:
From baseline up to 52 weeks
Reported as:
Count of participants · Participants
Safety - Number of Participants With All Bleeding
ParticipantsAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
Safety - Number of Participants With All Bleeding70758285
SecondarySafety - Number of Participants With BARC Bleeding Definition Type 3, 5

Type 3a: 1) overt bleed + Hg drop of 3 to \<5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation.

Time frame:
From baseline up to 52 weeks
Reported as:
Count of participants · Participants
Safety - Number of Participants With BARC Bleeding Definition Type 3, 5
ParticipantsAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
Safety - Number of Participants With BARC Bleeding Definition Type 3, 55335
SecondarySafety - Number of Participants With BARC Bleeding Definition Type 1,2,3,5

Type 1: bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional. For BARC bleeding definition 2,3 and 5, please refer to second primary endpoint.

Time frame:
From baseline up to 52 weeks
Reported as:
Count of participants · Participants
Safety - Number of Participants With BARC Bleeding Definition Type 1,2,3,5
ParticipantsAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
Safety - Number of Participants With BARC Bleeding Definition Type 1,2,3,570758285

Adverse events

Collected over After the first administration of study intervention for up to 52 weeks (but not starting after more than 2 days after the last administration). Reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact, for up to 54 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Asundexian 10 mg10/397 (2.5%)74/395 (18.7%)89/395 (22.5%)
Asundexian 20 mg7/401 (1.7%)82/397 (20.7%)118/397 (29.7%)
Asundexian 50 mg10/402 (2.5%)67/402 (16.7%)94/402 (23.4%)
Placebo7/401 (1.7%)82/399 (20.6%)107/399 (26.8%)
Most frequent serious events
Showing 10 of 182
Most frequent serious events
EventAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
Acute myocardial infarctionCardiac disorders9/3959/39710/4028/399
COVID-19Infections and infestations1/3951/3977/4025/399
Angina pectorisCardiac disorders5/3954/3976/4021/399
Chest painGeneral disorders4/3955/3974/4024/399
Cardiac failureCardiac disorders3/3954/3972/4025/399
Angina unstableCardiac disorders4/3951/3972/4024/399
COVID-19 pneumoniaInfections and infestations1/3950/3971/4024/399
Cardiac arrestCardiac disorders3/3951/3971/4021/399
AppendicitisInfections and infestations3/3950/3970/4020/399
Myocardial infarctionCardiac disorders2/3952/3973/4023/399
Most frequent other events
Most frequent other events
EventAsundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlacebo
HypertensionVascular disorders22/39527/39715/40230/399
Chest painGeneral disorders13/39529/39715/40217/399
DyspnoeaRespiratory, thoracic and mediastinal disorders21/39527/39721/40223/399
DiarrhoeaGastrointestinal disorders22/39521/39722/40218/399
DizzinessNervous system disorders18/39519/39721/40219/399
EpistaxisRespiratory, thoracic and mediastinal disorders17/39519/39721/40220/399

Baseline characteristics

FAS(Full data analysis)

Age, Categorical
Age, Categorical(Participants)Asundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlaceboTotal
<=18 years00000
Between 18 and 65 years122123118136499
>=65 years2752782842651102
Sex: Female, Male
Sex: Female, Male(Participants)Asundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlaceboTotal
Female938710090370
Male3043143023111231
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Asundexian 10 mgAsundexian 20 mgAsundexian 50 mgPlaceboTotal
American Indian or Alaska Native12003
Asian53505050203
Native Hawaiian or Other Pacific Islander00000
Black or African American32218
White3343453473391365
More than one race10225
Unknown or Not Reported521917
08

Study locations

160 sites
  • Valley Clinical Trials, Inc. - Covina
    Covina, California 91723, United States
  • Florida Premier Cardiology
    Boynton Beach, Florida 33437, United States
  • Clearwater Cardiovascular Associates | Clearwater, FL
    Clearwater, Florida 33756, United States
  • Cardiology Associates Research Company
    Daytona Beach, Florida 32117, United States
  • Southwest Florida Research
    Naples, Florida 34102, United States
  • Cardiology Partners Clinical Research Institute
    Palm Beach Gardens, Florida 33410, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Reid Health
    Richmond, Indiana 47374, United States
  • Midwest Heart & Vascular Specialists
    Overland Park, Kansas 66211, United States
  • Cardiovascular Associates Research, LLC
    Covington, Louisiana 70433, United States
  • Southern Clinical Research, LLC
    Zachary, Louisiana 70791, United States
  • Maryland Cardiovascular Specialists
    Baltimore, Maryland 21229, United States
  • White Oak Medical Center
    Silver Spring, Maryland 20904, United States
  • St. Mary's/Duluth Clinic Health System
    Duluth, Minnesota 55805, United States
  • Logan Health Research
    Kalispell, Montana 59901, United States
  • Methodist Physicians Clinic
    Omaha, Nebraska 68114, United States
  • The Valley Hospital, Inc.
    Ridgewood, New Jersey 07450, United States
  • Trinity Medical WNY
    Cheektowaga, New York 14227, United States
  • Jefferson Heart Institute
    Philadelphia, Pennsylvania 19107, United States
  • Cardiovascular Research of Knoxville
    Powell, Tennessee 37849, United States
  • PharmaTex Research, LLC
    Amarillo, Texas 79109, United States
  • North Texas Research Associates
    McKinney, Texas 75071, United States
  • Klinikum Klagenfurt am Wörthersee
    Klagenfurt, Kärnten 9020, Austria
  • Universitätsklinikum St. Pölten
    St. Pölten, Niederösterreich 3100, Austria
  • Landesklinikum Wiener Neustadt
    Wiener Neustadt, Niederösterreich 2700, Austria
  • Krankenhaus St. Josef Braunau
    Braunau, Oberösterreich 5280, Austria
  • Kepler Universitätsklinikum Campus III
    Linz, Oberösterreich 4021, Austria
  • Medizinische Universität Graz
    Graz, Steiermark 8036, Austria
  • Universitätsklinikum AKH Wien
    Wien, 1090, Austria
  • Klinik Ottakring - Wilhelminenspital
    Wien, 1160, Austria
  • Klinik Floridsdorf - Krankenhaus Nord
    Wien, 1210, Austria
  • OL Vrouwziekenhuis - Campus Aalst
    Aalst, 9300, Belgium
  • Imeldaziekenhuis - St-Elisabethkliniek
    Bonheiden, 2820, Belgium
  • AZ Sint-Jan Brugge-Oostende | Sint-Jan - Cardiology
    Brugge, 8000, Belgium
  • CU Saint-Luc/UZ St-Luc
    Bruxelles - Brussel, 1200, Belgium
  • Ziekenhuis Oost-Limburg
    Genk, 3600, Belgium
  • Jessa Ziekenhuis
    Hasselt, 3500, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • CHR de la Citadelle - Cardiology
    Liege, 4000, Belgium
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice u sv. Anny
    Brno, 656 91, Czechia
  • Nemocnice Ceske Budejovice, a.s. Department of kardiologie
    Ceske Budejovice, 370 01, Czechia
  • Fakultni Nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Fakultni nemocnice Plzen - Lochotin
    Plzen, 304 60, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 10, 10034, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 12808, Czechia
  • Institut Klinicke a Experimentalni Mediciny
    Praha 4, 140 21, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, 150 06, Czechia
  • Ustredni vojenska nemocnice Praha
    Praha 6, 169 02, Czechia
  • Nemocnice Slany
    Slany, 274 01, Czechia
  • Universitätsherzzentrum Freiburg - Bad Krozingen
    Bad Krozingen, Baden-Württemberg 79189, Germany
  • Universitätsklinikum Essen
    Essen, Nordrhein-Westfalen 45147, Germany
  • St. Vinzenz-Hospital
    Köln, Nordrhein-Westfalen 50733, Germany
  • Kliniken Maria Hilf GmbH
    Mönchengladbach, Nordrhein-Westfalen 41063, Germany
  • Sana-Klinikum Remscheid GmbH
    Remscheid, Nordrhein-Westfalen 42859, Germany
  • Forschungszentrum Ruhr - KliFoCenter GmbH
    Witten, Nordrhein-Westfalen 58455, Germany
  • Universitätsmedizin der Johannes Gutenberg Universität Mainz
    Mainz, Rheinland-Pfalz 55131, Germany
  • Krankenhaus Dresden-Friedrichstadt
    Dresden, Sachsen 01067, Germany
  • Universitätsklinikum Hamburg Eppendorf (UKE)
    Hamburg, 20246, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Allami Szivkorhaz
    Balatonfured, 8230, Hungary
  • Budai Irgalmasrendi Korhaz
    Budapest, 1023, Hungary
  • University of Semmelweis/ Semmelweis Egyetem
    Budapest, 1122, Hungary
  • Eszak-Pesti Centrumkorhaz-Honvedkorhaz
    Budapest, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Gyor, 9023, Hungary
  • Pandy Kalman Korhaz
    Gyula, 5700, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz
    Kaposvar, 7400, Hungary
  • Josa Andras Hospital
    Nyiregyhaza, H-4400, Hungary
  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz
    Szolnok, 5000, Hungary
  • Zala Megyei Szent Rafael Korhaz
    Zalaegerszeg, 8900, Hungary
  • A.O. San Pio
    Benevento, Campania 82100, Italy
  • ASL Caserta
    Caserta, Campania 81031, Italy
  • A.O.U. di Ferrara
    Ferrara, Emilia-Romagna 44124, Italy
  • Asl Roma 2
    Roma, Lazio 00157, Italy
  • IRCCS Ospedale Policlinico San Martino
    Genova, Liguria 16132, Italy
  • Istituto Clinico Humanitas - Humanitas Mirasole S.p.A.
    Milano, Lombardia 20089, Italy
  • IRCCS Centro Cardiologico Monzino S.p.A
    Milano, Lombardia 20138, Italy
  • ASST Valle Olona
    Varese, Lombardia 21047, Italy
  • A.O.U. Ospedali Riuniti "Umberto I - G.M.Lancisi - G.Salesi"
    Ancona, Marche 60126, Italy
  • A.O. S.Croce e Carle
    Cuneo, Piemonte 12100, Italy
  • ASL TO3 di Collegno e Pinerolo
    Torino, Piemonte 10098, Italy
  • A.O.U. di Sassari
    Sassari, Sardegna, Italy
  • AUSL Toscana Sud-Est
    Grosseto, Toscana 58100, Italy
  • ULSS3 Serenissima
    Venezia, Veneto 30035, Italy
  • Daido Hospital, Social Medical Corporation Kojunkai
    Nagoya, Aichi 457-8511, Japan
  • Chiba-Nishi General Hospital
    Matsudo, Chiba 270-2251, Japan
  • Fukuoka Tokushukai Hospital
    Kasuga, Fukuoka 816-0864, Japan
  • Kokura Memorial Hospital
    Kitakyushu, Fukuoka 802-8555, Japan
  • Ogaki Municipal Hospital
    Ogaki, Gifu 503-8502, Japan
  • Hokkaido Cardiovascular Hospital
    Sapporo, Hokkaido 064-8622, Japan
  • Hyogo Prefectural Harima-Himeji General Medical Center
    Himeji, Hyogo 670-8560, Japan
  • Takahashi Hospital
    Kobe, Hyogo 654-0026, Japan
  • Nishinomiya Watanabe Cardiovascular Center
    Nishinomiya, Hyogo 662-0911, Japan
  • Tsukuba Medical Center Hospital
    Tsukuba, Ibaraki 305-8558, Japan
  • Kanagawa Cardiovascular and Respiratory Center
    Yokohama, Kanagawa 236-0051, Japan
  • Kishiwada Tokushukai Hospital
    Kishiwada, Osaka 596-0042, Japan
  • Shin-Kuki General Hospital
    Kuki, Saitama 346-8530, Japan
  • Saitama Sekishinkai Hospital
    Sayama, Saitama 350-1305, Japan
  • Tokyo Medical and Dental University Hospital
    Bunkyo-ku, Tokyo 113-8519, Japan

Showing the first 100 of 160 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L, Hermanides RS, Campo G, Ferreiro JL, Shibasaki T, Mundl H, Alexander JH; PACIFIC AMI Investigators. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation. 2022 Oct 18;146(16):1196-1206. doi: 10.1161/CIRCULATIONAHA.122.061612. Epub 2022 Aug 27. Erratum In: Circulation. 2022 Dec 6;146(23):e330. doi: 10.1161/CIR.0000000000001115. PubMed 36030390 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Feb 2022, 20 months.

Results were first posted in Apr 2023, 1 year 1 month after primary completion.

Of 45 phase 2 interventional studies under Myocardial Infarction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2020
First posted
Mar 11, 2020
StartActual
Jun 17, 2020
Primary completionActual
Feb 21, 2022
CompletionActual
Feb 21, 2022
Results first posted
Apr 5, 2023
Last update
Apr 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04304534
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 11, 2020
Start date
Jun 17, 2020
Primary completion
Feb 21, 2022
Completion
Feb 21, 2022
Results posted
Apr 5, 2023
Last update
Apr 5, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asundexian

Start the discussion